RDAF Webinar on Rare Diseases in Switzerland – Report Published

    19 Apr, 2021

    The Rare Disease Action Forum (RDAF) published the report about its webinar “Access to diagnosis and treatment of rare diseases in Switzerland – Current status, challenges and initiatives”, which took place on 25 March 2021. The report gives an overview of the presentations held by experts in the field of rare diseases. In a multi-stakeholder approach, the webinar provided complementary perspectives presented by healthcare professionals and representatives from patient organizations and the industry. The speakers highlighted the challenges faced by patients with rare diseases, detailed the regulatory pathways for the orphan drug designation and shared their insights on access to treatment for rare diseases in Switzerland. The panel discussion focused on topics such as the institutional set-up of the RDAF, its current initiatives to improve access to treatment for rare diseases and potential solutions to improve the reimbursement regime for orphan drugs, which are not on the specialties list.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...